X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6359) 6359
Newsletter (55) 55
Magazine Article (15) 15
Dissertation (6) 6
Book Chapter (3) 3
Newspaper Article (3) 3
Paper (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3990) 3990
male (3382) 3382
animals (2924) 2924
female (2448) 2448
quinolines - administration & dosage (2310) 2310
quinolines - pharmacology (2289) 2289
quinolines - therapeutic use (1844) 1844
pharmacology & pharmacy (1482) 1482
adult (1437) 1437
rats (1244) 1244
middle aged (1237) 1237
mice (1117) 1117
quinolines - adverse effects (848) 848
dose-response relationship, drug (803) 803
fluoroquinolones (800) 800
aged (787) 787
treatment outcome (769) 769
administration, oral (731) 731
quinolines - pharmacokinetics (709) 709
adolescent (680) 680
oncology (611) 611
drug therapy, combination (555) 555
double-blind method (536) 536
montelukast (532) 532
moxifloxacin (512) 512
acetates - therapeutic use (503) 503
asthma - drug therapy (503) 503
acetates - administration & dosage (499) 499
research (494) 494
time factors (490) 490
analysis (482) 482
quinoline (451) 451
asthma (449) 449
pharmacokinetics (449) 449
drug therapy (444) 444
rats, sprague-dawley (428) 428
child (421) 421
aza compounds - administration & dosage (405) 405
cancer (405) 405
quinolines - chemistry (380) 380
disease models, animal (373) 373
immunology (366) 366
infectious diseases (356) 356
young adult (351) 351
quinolines (341) 341
expression (338) 338
care and treatment (337) 337
health aspects (327) 327
cell line, tumor (318) 318
microbiology (316) 316
neurosciences (305) 305
quinolines - blood (303) 303
leukotriene antagonists - therapeutic use (301) 301
safety (295) 295
therapy (295) 295
drug administration schedule (289) 289
inflammation (289) 289
quinolines - metabolism (286) 286
aza compounds - therapeutic use (285) 285
dosage and administration (284) 284
respiratory system (279) 279
chemistry, medicinal (277) 277
in-vitro (276) 276
efficacy (273) 273
medicine & public health (272) 272
rats, wistar (268) 268
biochemistry & molecular biology (265) 265
pharmacology (262) 262
malaria (259) 259
research article (258) 258
allergy (257) 257
child, preschool (255) 255
leukotriene antagonists - administration & dosage (254) 254
drugs (250) 250
children (249) 249
cross-over studies (246) 246
anti-asthmatic agents - therapeutic use (245) 245
apoptosis (244) 244
clinical trials (244) 244
pharmacology/toxicology (243) 243
aged, 80 and over (242) 242
double-blind (241) 241
prospective studies (241) 241
drug interactions (238) 238
ciprofloxacin (237) 237
anti-asthmatic agents - administration & dosage (235) 235
anti-bacterial agents - administration & dosage (230) 230
abridged index medicus (226) 226
activation (220) 220
administration, inhalation (220) 220
microbial sensitivity tests (220) 220
inhibition (218) 218
aza compounds - pharmacokinetics (211) 211
mice, inbred c57bl (205) 205
toxicology (204) 204
proteins (203) 203
quinolines - toxicity (203) 203
resistance (203) 203
cardiac & cardiovascular systems (201) 201
acetates - pharmacology (199) 199
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6203) 6203
German (76) 76
Japanese (64) 64
French (56) 56
Russian (38) 38
Chinese (24) 24
Spanish (20) 20
Italian (8) 8
Portuguese (5) 5
Polish (4) 4
Ukrainian (4) 4
Hungarian (3) 3
Turkish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2010, Volume 362, Issue 11, pp. 975 - 985
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2013, Volume 13, Issue 1, pp. 27 - 35
Summary Background Intensified antibiotic treatment might improve the outcome of tuberculous meningitis. We assessed pharmacokinetics, safety, and survival... 
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | ETHAMBUTOL | INFECTIOUS DISEASES | IN-VITRO | PHARMACOKINETICS | LEVOFLOXACIN | PULMONARY TUBERCULOSIS | INFECTION | DRUG-RESISTANCE | CEREBROSPINAL-FLUID | CIPROFLOXACIN | Fluoroquinolones | Aza Compounds - pharmacokinetics | Antitubercular Agents - adverse effects | Rifampin - pharmacokinetics | Antibiotics, Antitubercular - adverse effects | Follow-Up Studies | Humans | Middle Aged | Aza Compounds - adverse effects | Male | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Drug Therapy, Combination - adverse effects | Rifampin - adverse effects | Adult | Female | Rifampin - administration & dosage | Antibiotics, Antitubercular - administration & dosage | Aza Compounds - administration & dosage | Anti-Infective Agents - adverse effects | Antibiotics, Antitubercular - pharmacokinetics | Tuberculosis, Meningeal - drug therapy | Drug Administration Schedule | Drug Therapy, Combination - methods | Anti-Infective Agents - administration & dosage | Antitubercular Agents - pharmacokinetics | Anti-Infective Agents - pharmacokinetics | Adolescent | Antitubercular Agents - administration & dosage | Tuberculosis, Meningeal - metabolism | Quinolines - adverse effects | Indonesia | Tuberculosis | Meningitis | Dosage and administration | Product development | Moxifloxacin | Universities and colleges | Rifampin | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 2015, Volume 168, Issue 1, pp. 69 - 81
Summary Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | MOLECULAR RESPONSES | DASATINIB | NILOTINIB | RESISTANT | INTERFERON-ALPHA | IN-VITRO | PATIENTS RECEIVING IMATINIB | INHIBITOR | HEMATOLOGY | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Haematological Malignancy
Journal Article
Journal Article
International Journal of Hematology, ISSN 0925-5710, 11/2017, Volume 106, Issue 5, pp. 591 - 611
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s12185-017-2330-1 Byline:... 
Medicine & Public Health | Hematology | Oncology | RISK ESSENTIAL THROMBOCYTHEMIA | PLUS INTERFERON-ALPHA | DIAGNOSED CHRONIC-PHASE | COMPLETE MOLECULAR REMISSION | STANDARD-DOSE IMATINIB | TYROSINE KINASE INHIBITOR | PATIENTS RECEIVING IMATINIB | STEM-CELL TRANSPLANTATION | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | INTERNATIONAL WORKING GROUP | Prognosis | Humans | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Risk | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Antineoplastic Agents - administration & dosage | Quinolines - administration & dosage | Myeloproliferative Disorders - genetics | Aspirin - administration & dosage | Nitriles - administration & dosage | Blood Transfusion | Pyridazines - administration & dosage | Quinazolines - administration & dosage | Aniline Compounds - administration & dosage | Myeloproliferative Disorders - therapy | Pyrimidines - administration & dosage | Japan | Myeloproliferative Disorders - classification | Phlebotomy | Hematopoietic Stem Cell Transplantation | Hydroxyurea - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - classification | Pyrazoles - administration & dosage | Algorithms | Dasatinib - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Tumors | Myeloid leukemia | Leukemia | Chronic myeloid leukemia | Lymphoid tissue | Tissues | Neoplasms | Hemopoiesis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2007, Volume 356, Issue 20, pp. 2027 - 2039
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2008, Volume 122, Issue 6, pp. 1127 - 1135.e8
Journal Article
Drug metabolism and disposition, ISSN 1521-009X, 2010, Volume 38, Issue 1, pp. 168 - 176
This study investigated the role of a multispecific organic anion transporter, Oatp1a4/ Slco1a4 , in drug transport across the blood-brain barrier. In vitro... 
LOCALIZATION | INVOLVEMENT | POLYPEPTIDE-2 | PENETRATION | PHARMACOLOGY & PHARMACY | RAT-BRAIN | OATP2 | BCRP/ABCG2 | 17-BETA-ESTRADIOL-D-17-BETA-GLUCURONIDE | CANCER RESISTANCE PROTEIN | P-GLYCOPROTEIN | Fluorobenzenes - pharmacokinetics | Gene Expression - genetics | Pyrimidines - blood | Humans | Ion Pumps - genetics | Fluorobenzenes - administration & dosage | Quinolines - administration & dosage | Pyrimidines - metabolism | Brain - metabolism | Quinolines - pharmacokinetics | Choroid Plexus - blood supply | ATP-Binding Cassette Transporters - genetics | Ochratoxins - administration & dosage | Cell Membrane - metabolism | Cerebral Cortex - drug effects | Capillaries - metabolism | Fluorobenzenes - metabolism | Tetrahydroisoquinolines - pharmacology | Organic Cation Transport Proteins - metabolism | Pravastatin - metabolism | Liver - metabolism | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Taurocholic Acid - administration & dosage | Pravastatin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - administration & dosage | Pyrimidines - pharmacokinetics | Mice | Kinetics | Organic Cation Transport Proteins - genetics | Pravastatin - pharmacokinetics | Sulfonamides - administration & dosage | Quinolines - blood | Digoxin - metabolism | Taurocholic Acid - metabolism | Choroid Plexus - metabolism | Taurocholic Acid - blood | Ochratoxins - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Ochratoxins - metabolism | Cerebral Cortex - metabolism | Organic Anion Transporters - metabolism | Brain - blood supply | Sulfonamides - blood | Organic Anion Transporters - genetics | Transfection | Fluorobenzenes - blood | Enkephalin, D-Penicillamine (2,5)- - pharmacokinetics | Recombinant Proteins - metabolism | Cell Line | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Recombinant Proteins - genetics | Blood-Brain Barrier - drug effects | Digoxin - pharmacokinetics | Quinolines - metabolism | Taurocholic Acid - pharmacokinetics | Liver - blood supply | Pharmaceutical Preparations - metabolism | Animals | Digoxin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - metabolism | Acridines - pharmacology | Sulfonamides - metabolism
Journal Article
Journal Article
Journal Article
Drug design, development and therapy, ISSN 1177-8881, 2015, Volume 9, pp. 4479 - 4499
Transforming growth factor-beta (TGF-beta) signaling regulates a wide range of biological processes. TGF-beta plays an important role in tumorigenesis and... 
LY2157299 | Clinical trials | TGF-β | TGF-βRI kinase inhibitor | ALK5 | Galunisertib | Cancer | CHEMISTRY, MEDICINAL | RECEPTOR-TYPE-II | MESENCHYMAL TRANSITION | BREAST-CANCER | TGF-beta | HEPATOCELLULAR-CARCINOMA | TGF-beta RI kinase inhibitor | PLASMA-LEVELS | THERAPEUTIC TARGET | REGULATORY T-CELLS | PHARMACOLOGY & PHARMACY | cancer | clinical trials | TUMOR-GROWTH | galunisertib | I KINASE INHIBITOR | Phosphorylation | Pyrazoles - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Antineoplastic Agents - adverse effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Molecular Structure | Heart Diseases - chemically induced | Pyrazoles - pharmacokinetics | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Administration, Oral | Quinolines - chemistry | Smad2 Protein - metabolism | Neoplasms - enzymology | Treatment Outcome | Antineoplastic Agents - chemistry | Drug Discovery | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Receptors, Transforming Growth Factor beta - antagonists & inhibitors | Receptors, Transforming Growth Factor beta - metabolism | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinolines - therapeutic use | Neoplasms - pathology |